Member Exclusive

Optogenetics sheds light on cardiotoxicity screening for new drugs

Researchers from the George Washington University (Washington D.C., USA) have developed an optogenetic technique for testing the cardiotoxicity of new drugs for heart arrhythmias.

Go to the profile of Lauren Pulling
May 13, 2016
1
1

Please sign in or register for FREE

Register to MedChemNet

MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.

Register

1 Comments

Go to the profile of Ramaswamy Narayanan
Ramaswamy Narayanan about 2 years ago

Cardio toxicity is a major liability for drugs in development and in the market. Early in the lead identification process, if it is possible to filter the compounds with potential cardio toxicity, failures can be avoided. This can make the clinical trials more efficient and can save millions of dollars. The High throughput capability to screen the compounds using cardiomyocytes by optical stimulation and optical recording described in this study could be a boon for the pharma industry.